GenAns Biotech
↗Beijing, China
GenAns Biotech is a next-generation gene therapy company dedicated to developing innovative treatments for central nervous system (CNS) and ophthalmic diseases. Founded by renowned neurobiologist Dr. Luo Minmin, the company leverages advanced neurological drug discovery and evaluation platforms to target complex brain disorders that traditional small molecules struggle to address.
The company's core technology involves AAV-based gene delivery and a functional protein screening platform. GenAns aims to halt disease progression and enhance cognitive function in patients suffering from conditions such as schizophrenia, Alzheimer's, and various vision impairments. It is headquartered in the Zhongguancun Life Science Park in Beijing, a major hub for biotech innovation in China.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Gene Therapy / CNS Therapeutics
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Angel+
Total Raised:$14.3M
Investors:Co-Win Ventures (凯风创投), Beijing Zhongguancun Venture Capital Development, Zhongfalingchuang, Beijing Municipal Medical and Health Industry Investment Fund, Doyee Capital
PIPELINE
Stage:Preclinical
Lead Drug Stage:IND-enabling
Modalities:Gene therapy, AAV, Functional proteins
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Beijing Institute of Brain Research (NIBS/CIBR), Zhongguancun Life Science Park
COMPETITION
Position:Emerging
Competitors:Neurocrine Biosciences, Belief BioMed, Neurophth Therapeutics, Jazz Pharmaceuticals, Intra-Cellular Therapies
LEADERSHIP
Key Executives:
Luo Minmin - Founder & Chief Scientist
Fu Xuemei - CEO & Chairperson
Scientific Founders:Dr. Luo Minmin
Board Members:Fu Xuemei, Luo Minmin
LINKS
Website:genans.cn
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with GenAns Biotech. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.